

Waldemar Tomczak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3930432/publications.pdf>

Version: 2024-02-01

29
papers

191
citations

1162889

8
h-index

1125617

13
g-index

29
all docs

29
docs citations

29
times ranked

435
citing authors

#	ARTICLE	IF	CITATIONS
1	A polygenic risk score for multiple myeloma risk prediction. <i>European Journal of Human Genetics</i> , 2022, 30, 474-479.	1.4	5
2	Reduced Percentage of CD14dimCD16+SLAN+ Monocytes Producing TNF and IL-12 as an Immunological Sign of CLL Progression. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3029.	1.8	3
3	In vivo, ex vivo and in vitro dasatinib activity in chronic lymphocytic leukemia. <i>Oncology Letters</i> , 2021, 21, 285.	0.8	4
4	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. <i>International Journal of Cancer</i> , 2021, 149, 327-336.	2.3	3
5	The prognostic impact of CD49d protein and mRNA expression in patients with chronic lymphocytic leukaemia. <i>Archives of Medical Science</i> , 2021, , .	0.4	0
6	Genetically determined telomere length and multiple myeloma risk and outcome. <i>Blood Cancer Journal</i> , 2021, 11, 74.	2.8	10
7	Prognostic Value of Tie2-Expressing Monocytes in Chronic Lymphocytic Leukemia Patients. <i>Cancers</i> , 2021, 13, 2817.	1.7	3
8	Efficacy of siltuximab in the treatment of idiopathic multicentric castlemann disease, the first Polish, real-world experience with long-term observation. <i>Leukemia and Lymphoma</i> , 2021, 62, 3031-3034.	0.6	4
9	Cereblon (<i>CRBN</i>) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium. <i>Leukemia and Lymphoma</i> , 2020, 61, 699-706.	0.6	3
10	High M-MDSC Percentage as a Negative Prognostic Factor in Chronic Lymphocytic Leukaemia. <i>Cancers</i> , 2020, 12, 2614.	1.7	16
11	Cofilin-1 Maintains Prosurvival Signaling in Chronic Lymphocytic Leukemia Cells. <i>Anticancer Research</i> , 2020, 40, 6327-6335.	0.5	0
12	TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2019, 67, 55-65.	1.0	5
13	Evaluation of the prognostic and predictive value of free light chains in patients with chronic lymphocytic leukemia – preliminary results. <i>Acta Haematologica Polonica</i> , 2019, 50, 15-20.	0.1	0
14	Intracellular IL-4 and IFN- γ expression in iNKT cells from patients with chronic lymphocytic leukemia. <i>Oncology Letters</i> , 2018, 15, 1580-1590.	0.8	12
15	Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. <i>British Journal of Haematology</i> , 2018, 183, 375-384.	1.2	11
16	Zespół hemofagocytowy indukowany terapią hormonalną... studium przypadku klinicznego. <i>Acta Haematologica Polonica</i> , 2018, 49, 151-156.	0.1	0
17	Identification of miRSNPs associated with the risk of multiple myeloma. <i>International Journal of Cancer</i> , 2017, 140, 526-534.	2.3	8
18	Laccase purified from <i>Cerrena unicolor</i> exerts antitumor activity against leukemic cells. <i>Oncology Letters</i> , 2016, 11, 2009-2018.	0.8	32

#	ARTICLE	IF	CITATIONS
19	Specific cytotoxic T cell immune responses against autoantigens recognized by chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2016, 174, 582-590.	1.2	3
20	Indirect induction of regulatory T cells accompanies immune responses during peptide vaccination of chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2016, 174, 155-157.	1.2	1
21	Detailed Clinical, Immunological and Molecular Analysis of NOTCH1, SF3B1 and MYD88 mutations in Chronic Lymphocytic Leukemia Patients Reveals Accumulation of Negative Prognostic Features in NOTCH1 and SF3B1 mutated Individuals. <i>Blood</i> , 2016, 128, 5570-5570.	0.6	0
22	The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2908-2913.	0.6	18
23	IL-6, IL-10, c-Jun and STAT3 expression in B-CLL. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 54, 258-265.	0.6	15
24	Cytotoxic Activity of Valproic Acid on Primary Chronic Lymphocytic Leukemia Cells. <i>Advances in Clinical and Experimental Medicine</i> , 2015, 24, 55-62.	0.6	6
25	CD1d expression is higher in chronic lymphocytic leukemia patients with unfavorable prognosis. <i>Leukemia Research</i> , 2014, 38, 435-442.	0.4	25
26	In Chronic Lymphocytic Leukemia PD-1 Is Expressed Independently From PDCD1 Gene Polymorphisms and Does Not Influence BCR Signaling. <i>Blood</i> , 2013, 122, 1625-1625.	0.6	1
27	Involvement Of Autoreactive T Lymphocytes In Pathogenesis Of Chronic Lymphocytic Leukemia (CLL): Specific T-Cell Immune Responses Against Autoantigens Recognized By CLL Cells. <i>Blood</i> , 2013, 122, 2859-2859.	0.6	0
28	Analysis of ex vivo Apoptosis of B and T cells from Peripheral Blood and Bone Marrow of Patients with Chronic Lymphocytic Leukemia. <i>Acta Haematologica Polonica</i> , 2012, 43, 336-341.	0.1	1
29	Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Myeloma Patients?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , .	1.1	2